読み込み中
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
終値時点
$1.99
+$0.01 · +0.51%
時間外
$1.98
−$0.01 · -0.50%
10月8日 16:10 ET
日中の時刻はETです。市場データは遅延する場合があります。
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
日中レンジ
現在 $1.99
52週レンジ
現在 $1.99
日中の時刻はETです。市場データは遅延する場合があります。
GoAI スコア
売り
バリュエーション
25
割高
センチメント
48
まちまち
リスク
64
高リスク
モメンタム
37
弱含み
GoAIの詳細リサーチ
詳しい根拠、カタリスト、リスクを確認できます。
XTL Biopharmaceuticals Ltd. is a biopharmaceutical firm dedicated to identifying and advancing novel drug therapies for autoimmune conditions. Its primary investigational compound, hCDR1, is poised to enter Phase II trials, specifically targeting systemic lupus erythematosus and Sjogren's syndrome. The company holds a crucial licensing agreement with Yeda Research and Development Company Limited, which grants rights for the research, development, and eventual commercialization of hCDR1 across multiple therapeutic indications. Originally established in 1993 as Xenograft Technologies Ltd., the company rebranded to XTL Biopharmaceuticals Ltd. in July 1995. It operates from its headquarters in Ramat Gan, Israel.
日中レンジ
現在 $1.99
52週レンジ
現在 $1.99
営業利益
純利益
| 指標（USD） | 2025年度 | 2024年度 | 2023年度 | 2022年度 | 2021年度 |
|---|---|---|---|---|---|
| 売上高 | — | 45.1万 USD | — | — | — |
| 売上原価 | — | 44.8万 USD | — | 1000 USD | 1000 USD |
| 粗利益 | — | 3000 USD | — | −1000 USD | −1000 USD |
| 研究開発 | 2.8万 USD | 9.8万 USD | 3.1万 USD | 3万 USD | 3万 USD |
| 販売・一般管理 | 112.9万 USD | 204.6万 USD | 73.4万 USD | 85万 USD | 100.1万 USD |
| 営業費用 | 168.8万 USD | 217.5万 USD | 76.5万 USD | 88万 USD | 103.1万 USD |
| 受取利息 | 6万 USD | 3.4万 USD | 4.1万 USD | 3.6万 USD | 8000 USD |
| 支払利息 | 7000 USD | 8.6万 USD | 3999 USD | 1.1万 USD | 2.1万 USD |
| 減価償却費と償却費 | — | 19.9万 USD | 1000 USD | 1000 USD | 1000 USD |
| 営業利益 | −168.8万 USD | −217.2万 USD | −76.5万 USD | −88万 USD | −103.1万 USD |
| 純利益 | −696.9万 USD | −102.7万 USD | −1782 USD | −134.8万 USD | 43.5万 USD |
会社概要が更新されました 2026年10月9日.
直近の発表実績
直近の発表実績
AIが生成した遅延市場データを、情報提供および教育目的で掲載しています。投資助言ではありません。
